News & Updates
Filter by Specialty:
Novel drug helps optimize HFrEF therapy
In individuals receiving renin-angiotensin-aldosterone system inhibitor (RAASi) therapy for heart failure with reduced ejection fraction (HFrEF), the novel potassium binder patiromer effectively reduced serum potassium levels, the DIAMOND trial suggests, thus optimizing a guideline-directed RAASi therapy for these patients.
Novel drug helps optimize HFrEF therapy
27 Apr 2022
Does metoprolol influence exercise haemodynamics in HCM?
Exercise contributes to an abnormal risk in pulmonary capillary wedge pressure (PCWP), but is not affected by metoprolol, in patients with obstructive hypertrophic cardiomyopathy (HCM), results of a study have shown.
Does metoprolol influence exercise haemodynamics in HCM?
26 Apr 2022
Cardiac deaths, neurologic injuries, multiorgan failures account for most AMICS deaths
The primary causes of death in patients with acute myocardial infarction complicated by cardiogenic shock (AMICS) are heart failure, neurologic injury, and multiorgan failure (MOF), reports a recent study. Deaths from cardiac causes often occur within 13 hours of the first medical contact.
Cardiac deaths, neurologic injuries, multiorgan failures account for most AMICS deaths
25 Apr 2022
Prolonged QTc in hospitalized COVID-19 patients tied to increased mortality risk
Prolonged corrected QT interval (QTc), as determined via electrocardiogram (ECG), may indicate an elevated risk of myocardial injury and death in patients hospitalized for COVID-19, according to a prospective study from Israel presented at EHRA 2022.